# Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events

> **NCT01572909** · PHASE2 · COMPLETED · sponsor: **Stealth BioTherapeutics Inc.** · enrollment: 300 (actual)

## Conditions studied

- Reperfusion Injury
- STEMI

## Interventions

- **DRUG:** Bendavia (MTP-131)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01572909
- **Lead sponsor:** Stealth BioTherapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2014-11
- **Final completion:** 2015-02
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2020-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01572909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01572909, "Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01572909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*